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Abstract
Background: The CRASH-2 trial showed that tranexamic acid (TXA) administration reduces mortality in bleeding
trauma patients. However, the effect appeared to depend on how soon after injury TXA treatment was started.
Treatment within 3 h reduced bleeding deaths whereas treatment after 3 h increased the risk. We examine how
patient characteristics vary by time to treatment and explore whether any such variations explain the time-
dependent treatment effect.
Methods: Exploratory analysis were carried out, including per-protocol analyses, of data from the CRASH-2 trial, a
randomised placebo-controlled trial of the effect of TXA on mortality in 20,211 trauma patients with, or at risk of,
significant bleeding. We examine how patient characteristics (age, type of injury, presence or absence of head
injury, Glasgow coma scale (GCS), systolic blood pressure and capillary refill time) vary with time to treatment and
use univariable (restriction) and multivariable methods to examine whether any such variations explain the time-
dependent effect of TXA. If not explained by differences in patient characteristics, we planned to conduct separate
prespecified subgroup analyses for the early benefit and late harm.
Results: There was no substantial variation in age or capillary refill by time to treatment. However, the proportion
of patients with blunt trauma, the proportion with head injury and mean systolic blood pressure increased as time
to treatment increased. Mean GCS decreased as time to treatment increased. Analyses restricted to patients with
blunt trauma, those without head injury and those with a systolic blood pressure <100 mmHg showed that these
characteristics did not explain the time-dependent treatment effect. In a multivariable analysis the interaction with
time to treatment remained highly significant (p < 0.0001). Separate subgroup analyses that examine how the
benefits of early TXA treatment and the harms of late TXA treatment vary by systolic blood pressure (≤75, 76–89,
>89 mmHg); GCS (severe 3–8, moderate 9–12, mild 13–15); and type of injury (penetrating versus blunt) showed no
significant heterogeneity.
Conclusions: The time-dependent effect of TXA in bleeding trauma patients is not explained by the type of injury,
the presence or absence of head injury or systolic blood pressure. When given within 3 h of injury, TXA reduces
death due to bleeding regardless of type of injury, GCS or blood pressure.
Trial registration: ClinicalTrials.gov, NCT00375258. Registered on 11 September 2006.
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Background
The CRASH-2 trial showed that administration of tran-
examic acid (TXA) to bleeding trauma patients who are
within 8 h of injury reduces death due to bleeding (rela-
tive risk (RR) = 0.85, 95% CI 0.76 to 0.96) and all-cause
mortality (RR = 0.91, 95% CI 0.85 to 0.97) [1]. However,
prespecified subgroup analyses showed that the effect of
TXA depends on the time interval between the injury
and the start of treatment [2]. Treatment initiated within
3 hours of injury significantly reduced death due to
bleeding (RR = 0.72, 95% CI 0.63 to 0.83), whereas initi-
ation after 3 hours increased the risk (RR = 1.44, 95% CI
1.21 to 1.84).
Although we expected that early treatment would be
more effective, we did not expect late treatment to
increase the risk of death due to bleeding. On biological
grounds, we anticipate treatments to have broadly simi-
lar effects on a given outcome and should be wary of
claims that a treatment is highly beneficial in one
subgroup but harmful in another [3]. The strong inter-
action with time to treatment suggests that patients
treated within 3 h of injury are different to those treated
after 3 h in ways that are relevant to the mechanism of
action of TXA [3]. For example, if TXA was harmful in
patients with head injury and such patients were under-
represented in those treated within 3 h but overrepre-
sented in those treated after 3 h, this might explain the
time-dependent treatment effect. We examine how pa-
tient characteristics vary by time to treatment in the
CRASH-2 trial and explore whether any such variations
explain the time-dependent treatment effect.
Methods
Study design and patients
The CRASH-2 trial was a randomised placebo-
controlled trial of the effect of TXA on death and vascu-
lar occlusive events in adult trauma patients with, or at
risk of, significant bleeding within 8 h of their injury.
After collecting baseline data on patient characteristics,
patients were randomly allocated to TXA (loading dose
1 g over 10 min followed by an infusion of 1 g over 8 h)
or matching placebo. The primary outcome was death in
hospital within 4 weeks of injury. We classified cause of
death into the following categories: bleeding, vascular
occlusion (myocardial infarction, stroke, and pulmonary
embolism), multiorgan failure, head injury and other.
Follow-up data were available for 99 · 6% of patients.
The trial was conducted in 274 hospitals in 40 countries.
We have previously published a detailed description of
the trial [1, 2].
Analysis
We described graphically the relationship between time
since injury and the following patient characteristics:
mean age, proportion with blunt trauma, proportion
with head injury, mean Glasgow Coma Scale (GCS)
score, mean systolic blood pressure (SBP) and mean
capillary refill time. If a characteristic varied by time to
treatment, we examined the impact of this variable on
the time to treatment interaction using univariable
(restriction) and multivariable methods.
For early and late treatment, we examined separately
how the effects of TXA treatment on deaths due to
bleeding vary according to patient characteristics in
the following subgroup analyses: SBP (≤75, 76–89,
>89 mmHg); GCS score (severe 3–8, moderate 9–12,
mild 13–15); type of injury (penetrating versus blunt).
All of these analyses were prespecified in the trial
protocol. Heterogeneity in effects across subgroups
was assessed by a χ2 test. We prespecified that unless
there was strong evidence against the null hypothesis
of homogeneity of effects (i.e. p < 0.001), the overall
relative risk would be considered the most reliable
guide to the approximate relative risks in all sub-
groups. Precision was quantified using 95% confidence
intervals (CI).
We assessed the evidence for interaction between
TXA and time since injury after adjusting for any inde-
pendent effects of SBP, GCS score and type of injury, as
well as any interactions between TXA and these charac-
teristics. For this we fitted multivariable logistic regres-
sion models and used likelihood ratio tests.
Results
Figure 1 shows the relationship between patient charac-
teristics and time from injury to treatment. There was
little variation in mean age or mean capillary refill by
time to treatment. However, the proportion of patients
with blunt trauma, the proportion with head injury and
mean SBP increased as time to treatment increased.
Mean GCS score decreased with increasing time to
treatment.
Table 1 shows the effect of TXA on death due to
bleeding stratified by time to treatment. There was
strong evidence of a time to treatment interaction. To
explore whether the time to treatment interaction was
explained by type of injury, we restricted the analyses to
patients with blunt trauma. Strong evidence of a time to
treatment interaction remained (p = 0.0001). Among pa-
tients with blunt trauma, treatment initiated within an
hour of injury reduced the risk of death due to bleeding
(RR = 0.68; 95% CI 0.53 to 0.87), as did treatment initi-
ated between 1 and 3 h (RR = 0.76; 95% CI 0.59 to 0.99),
whereas treatment beyond 3 h increased the risk of
death due to bleeding (RR = 1.48; 95% CI 1.12 to 1.96).
To explore whether the time to treatment inter-
action was explained by the presence or absence of
head injury, we restricted the analyses to patients
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without head injury. Strong evidence of an interaction
remained (p = 0.0001). Among patients without head
injury, treatment initiated within an hour of injury
reduced the risk of death due to bleeding (RR = 0.64; 95%
CI 0.52 to 0.78), as did treatment initiated between 1 and
3 h (RR = 0.71; 95% CI 0.55 to 0.91), whereas treatment
beyond 3 h increased the risk of death due to bleeding
(RR = 1.41; 95% CI 1.05 to 1.90).
To explore whether the time to treatment interaction
was explained by SBP, we restricted the analyses to pa-
tients with a SBP <100 mmHg. Strong evidence of an
interaction remained (p = 0.0001). Among patients with
SPB <100 mmHg, treatment initiated within an hour of
injury reduced the risk of death due to bleeding (RR =
0.69; 95% CI 0.58 to 0.83), as did treatment initiated be-
tween 1 and 3 h (RR = 0.84; 95% CI 0.67 to 1.04),
whereas treatment beyond 3 h increased the risk of
death due to bleeding (RR = 1.52; 95% CI 1.15 to 2.00).
After adjusting for any independent effects on deaths
due to bleeding of SBP, GCS score and type of injury,
the time to treatment interaction remained strong and
highly statistically significant (p < 0.0001). As a sensitivity
analysis, we tested for confounding of the time to treat-
ment interaction (Appendix). After controlling for con-
founders, the treatment-time interaction remained in the
case of models with SBP and type of injury, although the
interaction was less obvious after controlling for GCS.
The extent to which the treatment group by time since
injury interaction varies by subgroup in illustrated pic-
torially in the Appendix.
Because the time to treatment interaction could not be
explained by differences in the characteristics of early
and late-treated patients, we conducted subgroup ana-
lyses to examine separately how the benefits of early
TXA treatment and the harms of late TXA treatment
vary by SBP (≤75, 76–89, >89 mmHg); GCS score
Fig. 1 Patient characteristics by time from injury to treatment
Table 1 Effect of tranexamic acid (TXA) on death due to bleeding by time from injury to initiation of treatment
Time to treatment (h) TXA allocated Placebo allocated Risk ratio (95% CI)
≤1 198/3747 (5 · 3%) 286/3704 (7 · 7%) 0 · 68 (0 · 57–0 · 82)
>1 to ≤3 147/3037 (4 · 8%) 184/2996 (6 · 1%) 0 · 79 (0 · 64–0 · 97)
>3 144/3272 (4 · 4%) 103/3362 (3 · 1%) 1 · 44 (1 · 12–1 · 84)
Interaction χ2 = 23 · 516, p < 0 · 0000
Roberts et al. Trials  (2017) 18:48 Page 3 of 6
(severe 3–8, moderate 9–12, mild 13–15); and type of
injury (penetrating versus blunt). Figure 2 shows the ef-
fects of early TXA treatment stratified by SBP, GCS and
type of injury. There was no significant heterogeneity.
Figure 3 shows the effects of late TXA treatment strati-
fied by SBP, GCS and type of injury. Once again, there
was no significant heterogeneity. As a more powerful
sensitivity analysis, we tested for subgroup effects on the
time by treatment interaction in a model including a
three-way interaction term. There was no significant
heterogeneity in the effect of TXA, according to SBP,
GCS and type of injury, when time to treatment was
taken into account.
Discussion
Patients in the CRASH-2 trial who were treated with
TXA within 3 h of injury were less likely to have blunt
trauma and head injury and had lower SBPs than those
treated after 3 h. However, these differences do not com-
pletely explain the strong time to treatment interaction,
although the interaction was not as obvious in patients
with a low GCS. When given within 3 h of injury, TXA
reduces death due to bleeding regardless of injury type,
GCS or blood pressure.
We have previously reported subgroup analyses of the
effect of TXA according to SBP, GCS and type of injury
[2]. All of these analyses were prespecified in the trial
protocol. However, because they ignore the time to
treatment interaction their value is limited. If TXA is ei-
ther beneficial or harmful depending on how soon after
injury the patient is treated, the overall effect regardless
of time to treatment is neither biologically relevant nor
generalisable since it depends largely on the proportion
of patients treated early or late in the trial. Having iden-
tified that the effect of TXA depends on time to treat-
ment, all other subgroup analyses should be conducted
separately for early or late-treated patients as we have
done here. The most striking observation from these
analyses is the absence of heterogeneity. Early treatment
appears effective and late treatment appears harmful in
all subgroups. These analyses provide no support for the
assertion that TXA is only indicated for patients with se-
vere shock (SPB <75 mmHg) [4]. Early treatment is ef-
fective regardless of SBP.
Recent results suggest biological explanations for the
time to treatment interaction. Early fibrinolysis is com-
mon after trauma and is associated with increased mor-
tality [5, 6]. Tissue plasminogen activator (TPA), the
enzyme that converts plasminogen to the fibrinolytic en-
zyme plasmin, is stored within the endothelium in
Weibel-Palade bodies. Trauma triggers the release of
TPA resulting in plasmin activation, fibrinolysis and pro-
fuse bleeding [7, 8]. TPA levels peak 30 min after injury
and plasmin levels peak around 1 h [8]. By inhibiting fi-
brinolysis, TXA prevents early exsanguination [9]. How-
ever, the effects are short lived. Around 2 h after injury
plasminogen activator inhibitor-1 (PAI-1) levels start to
increase reaching a peak around 3 h [8]. PAI-1 inhibits
fibrinolysis resulting in ‘fibrinolytic shutdown’ [10]. This
might explain why the benefits of TXA treatment are
Fig. 2 Effects of early tranexamic acid (TXA) treatment stratified by systolic blood pressure (SBP), Glasgow Coma Scale (GCS) score and type
of injury
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limited to the first 3 h. The adverse effects of late TXA
administration may be due to PAI-1-induced suppres-
sion of fibrinolysis and the onset of thrombotic dissemi-
nated intravascular coagulation (DIC). By inhibiting
fibrinolysis TXA could worsen DIC. Although the path-
ology is thrombotic, due to the consumption of clotting
factors, thrombotic DIC usually manifests clinically as
bleeding [9].
The differential effects of TXA on TPA and urokinase
plasminogen activator (UPA)-mediated plasminogen ac-
tivation have also been proposed as a potential biological
explanation of the ‘TXA paradox’ of time-dependent ef-
fects [11]. Although TXA inhibits TPA-mediated fibrin-
olysis, it stimulates fibrinolysis mediated by UPA [12].
The binding of TXA to plasminogen results in a con-
formational change in the plasminogen molecule that
makes it more readily cleaved by UPA. The potential
clinical importance of this finding is highlighted in ani-
mal models of the effect of TXA in closed head injury
[13]. Two hours after injury, TXA treatment reduced
intracranial bleeding consistent with the inhibition of
TPA-mediated fibrinolysis [13]. However, when given
8 h after injury, when UPA levels were highest, TXA in-
creased intracranial bleeding [13].
Conclusions
All trauma patients with potentially life-threatening
bleeding within 3 h of injury should be treated with
TXA regardless of blood pressure, GCS or type of injury.
Treatment after 3 h appears to increase the risk of death
due to bleeding and, therefore, is contraindicated. Al-
though it has been suggested that thromboelastography
can be used to further subdivide patients into those that
will benefit from TXA and those that will not, further
research is needed [10, 14]. Whether TXA reduces mor-
tality in isolated traumatic intracranial, gastrointestinal
and postpartum bleeding and whether any such effect
depends on time to treatment is open to question but
will be informed by the results of large-scale clinical tri-
als in these areas [15–17].
Key messages
 Tranexamic acid reduces mortality in bleeding
trauma patients but the effect appears to depend on
time to treatment. Early treatment reduced bleeding
deaths whereas late treatment increased the risk. We
examined how patient characteristics vary by time
to treatment and whether such variations explain
the time-dependent treatment effect
 Patients treated within 3 h were less likely to have
blunt trauma and head injury and had lower SBPs
than those treated after 3 h. These differences do
not completely explain the strong time to treatment
interaction, although the interaction was not as
obvious in patients with a low score on the GCS
 When given within 3 h of injury, TXA reduces death
due to bleeding regardless of the type of injury, GCS
or SBP. Treatment after 3 h increases the risk of
death due to bleeding
Fig. 3 Effects of late tranexamic acid (TXA) treatment stratified by systolic blood pressure (SBP), Glasgow Coma Scale (GCS) score and type
of injury
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